Cargando...
P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA
Bevacizumab is registered in the U.S. for the treatment of recurrent glioblastoma based on improved PFS in uncontrolled phase II trials; Recently, a randomized controlled phase II trial studied lomustin, bevacizumab or the combination of both compounds in the treatment of glioblastoma at first recur...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4185719/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.352 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|